

**INTELLIGENT INGESTIBLE SENSOR SYSTEMS FOR MEDICATION ADHERENCE:  
CLINICAL APPLICATIONS, TECHNOLOGICAL INNOVATIONS, AND ETHICAL  
CHALLENGES**Nidhi Chauhan<sup>1\*</sup>, Bhavaniben Miteshbhai Patel<sup>2</sup>, Vijay Oza<sup>3</sup>, Kirti Gohil<sup>4</sup>, Parekh Prerna<sup>5</sup>

Department of Pharmacy, Laxminarayan Dev College of pharmacy, Bholav, Bharuch - 392015.

Article Received: 20 May 2026

Article Revised: 10 June 2026

Article Published: 01 July 2026



\*Corresponding Author: Nidhi Chauhan

Department of Pharmacy, Laxminarayan Dev College of pharmacy, Bholav, Bharuch - 392015.

DOI: <https://doi.org/10.5281/zenodo.21021843>

**How to cite this Article:** Nidhi Chauhan<sup>1\*</sup>, Bhavaniben Miteshbhai Patel<sup>2</sup>, Vijay Oza<sup>3</sup>, Kirti Gohil<sup>4</sup>, Parekh Prerna<sup>5</sup>. (2026). Intelligent Ingestible Sensor Systems For Medication Adherence: Clinical Applications, Technological Innovations, And Ethical Challenges. World Journal of Advance Healthcare Research, 10(7), 14–18.  
This work is licensed under Creative Commons Attribution 4.0 International license.

**ABSTRACT**

Digital pill systems represent a transformative advancement in digital medicine, combining pharmaceuticals with ingestible sensors to monitor medication adherence in real time. Medication nonadherence remains a significant global healthcare challenge, contributing to poor therapeutic outcomes, increased hospitalizations, and higher healthcare costs. Digital pills integrate ingestible sensors, wearable receivers, and mobile health applications to provide objective confirmation of medication ingestion. This review aims to provide a comprehensive overview of digital pill technology, its mechanism of action, clinical applications, advantages, limitations, regulatory considerations, and ethical implications. Evidence from recent clinical studies demonstrates that digital pills improve adherence in chronic diseases, psychiatric disorders, infectious diseases, and post-transplant care. However, challenges such as cost, patient privacy, data security, and accessibility remain barriers to widespread adoption. Future developments are expected to include artificial intelligence integration, enhanced sensor miniaturization, and improved patient-centered healthcare delivery. Digital pill systems have the potential to revolutionize medication management and personalized medicine if implemented responsibly and ethically.

**KEYWORDS:** Digital pills, ingestible sensors, medication adherence, digital medicine, telehealth, healthcare technology.

**1. INTRODUCTION**

Medication adherence is a critical determinant of therapeutic success in both acute and chronic diseases. According to global health reports, approximately **50% of patients with chronic diseases fail to take medications as prescribed**, leading to treatment failure, disease progression, and increased mortality.<sup>[1]</sup> Nonadherence is particularly problematic in conditions requiring long-term therapy, including hypertension, diabetes, tuberculosis, and psychiatric disorders.<sup>[2]</sup>

Traditional methods of monitoring medication adherence—such as pill counts, patient self-reports, and pharmacy refill records—are often unreliable and subjective.<sup>[3]</sup> The emergence of digital health technologies has provided innovative solutions to address these limitations. Among these innovations, **digital pill systems**, also known as ingestible sensor

technologies, have gained significant attention in recent years.

A digital pill consists of a medication embedded with a miniature ingestible sensor capable of transmitting a signal upon ingestion. This signal is detected by a wearable device and transmitted to a mobile application or healthcare system for monitoring and analysis.<sup>[4]</sup> The first digital pill approved for clinical use marked a milestone in digital medicine and demonstrated the feasibility of real-time adherence monitoring.

Digital pill technology represents a convergence of biomedical engineering, pharmacology, and information technology, enabling healthcare providers to track medication adherence objectively. This review provides a detailed overview of digital pill systems, including

their technological components, clinical applications, benefits, challenges, and ethical considerations.




Fig 1 Overview of Digital Pill Technology

**2. Overview of Digital Pill Technology**

Digital pill systems are advanced healthcare technologies designed to monitor medication ingestion using ingestible sensors and wireless communication systems.

**2.1 Components of Digital Pill Systems**

Digital pill systems typically consist of three main components:

**1. Ingestible Sensor**

The ingestible sensor is a miniature electronic device embedded within a pharmaceutical tablet or capsule. These sensors are constructed from biocompatible materials such as:

- Magnesium
- Copper
- Silicon

When the pill reaches the stomach, gastric fluids activate the sensor, generating a small electrical signal that confirms ingestion.<sup>[5]</sup>

**2. Wearable Receiver or Patch**

A wearable patch placed on the patient’s body detects the signal transmitted by the ingestible sensor. The patch performs multiple functions:

- Detects ingestion events
- Records physiological parameters
- Stores and transmits data
- Monitors patient activity

The patch typically communicates with mobile devices using wireless technologies such as Bluetooth.<sup>[6]</sup>

**3. Mobile Application or Cloud Platform**

The mobile application serves as the interface between patients and healthcare providers. It allows:

- Real-time medication tracking
- Data storage and analysis
- Medication reminders
- Communication with clinicians

These applications support remote monitoring and telemedicine services.<sup>[7]</sup>

**2.2 Mechanism of Action**

The digital pill system operates through a sequence of events:

1. The patient ingests the digital pill
2. Gastric fluid activates the sensor
3. The sensor generates an electrical signal
4. The wearable patch detects the signal
5. Data is transmitted to a mobile application
6. Healthcare providers access adherence data

This mechanism enables objective confirmation of medication ingestion, improving treatment monitoring and patient engagement.<sup>[8]</sup>

**3. Clinical Applications of Digital Pill Systems**

Digital pill systems have demonstrated effectiveness in improving medication adherence across multiple therapeutic areas.

**3.1 Psychiatry and Mental Health**

Medication adherence is essential in managing psychiatric disorders such as:

- Schizophrenia
- Bipolar disorder
- Major depressive disorder

Digital pill systems allow clinicians to monitor adherence and identify missed doses early. Studies have shown improved treatment outcomes and reduced relapse rates among patients using digital pill technology.<sup>[9]</sup>

**3.2 Infectious Diseases**

Digital pills have been widely investigated in infectious disease management, particularly:

- Tuberculosis
- HIV/AIDS

Adherence to antimicrobial therapy is critical for preventing drug resistance and treatment failure. Digital adherence technologies have demonstrated improved treatment completion rates in tuberculosis patients.<sup>[10]</sup>

**3.3 Organ Transplantation**

Organ transplant recipients require lifelong immunosuppressive therapy to prevent organ rejection. Even minor lapses in medication adherence can result in serious complications. Digital pill systems help monitor adherence and support early intervention by healthcare providers.<sup>[11]</sup>

**3.4 Chronic Diseases**

Digital pills are increasingly used in chronic disease management, including:

- Diabetes mellitus
- Hypertension
- Cardiovascular disease

These systems provide real-time monitoring and personalized treatment adjustments, improving patient outcomes and reducing healthcare costs.<sup>[12]</sup>

**3.5 Clinical Trials**

Digital pill systems are also used in clinical research to monitor medication adherence during drug trials. Accurate adherence data improves the reliability of clinical trial results and supports regulatory approval processes.<sup>[13]</sup>

**Table 1: Summary of therapeutic areas where digital pill systems have been applied.**

Therapeutic Area	Examples of Use
Psychiatry	Schizophrenia, Bipolar Disorder, Depression (Abilify MyCite®)
Infectious Diseases	HIV, Tuberculosis (ID-Cap™)
Organ Transplantation	Monitoring immunosuppressant intake
Chronic Diseases	Hypertension, Diabetes, Heart disease
Clinical Trials	Real-time adherence tracking for study drugs

**4. Advantages of Digital Pill Systems**

Digital pill systems offer several benefits in healthcare delivery:

**4.1 Improved Medication Adherence**

Real-time monitoring ensures patients follow prescribed treatment regimens, reducing complications and hospitalizations.<sup>[14]</sup>

**4.2 Enhanced Patient Engagement**

Digital health technologies encourage patients to actively participate in their treatment and improve communication with healthcare providers.<sup>[15]</sup>

**4.3 Accurate Data Collection**

Digital pills provide objective adherence data, eliminating reliance on patient self-reporting.<sup>[16]</sup>

**4.4 Personalized Medicine**

Data collected from digital pill systems can be used to tailor treatment plans according to individual patient needs.<sup>[17]</sup>

**5. Limitations and Challenges**

Despite their benefits, digital pill systems face several limitations.

**5.1 High Cost**

The cost of digital pill technology remains a significant barrier to widespread adoption, particularly in low-resource settings.<sup>[18]</sup>

**5.2 Technical Issues**

Technical challenges include:

- Device malfunction
- Connectivity problems
- Battery limitations

These issues may affect system reliability.<sup>[19]</sup>

**5.3 Patient Acceptance**

Some patients may be reluctant to use digital pills due to concerns about privacy or technological complexity (20).

**6. Ethical and Legal Considerations**

Digital pill systems raise important ethical, legal, and social concerns.

**6.1 Privacy and Data Security**

Digital pills collect sensitive health data that must be protected from unauthorized access. Data breaches can compromise patient confidentiality.<sup>[21]</sup>

## 6.2 Informed Consent

Patients must fully understand how digital pill systems work and provide voluntary consent before using the technology.<sup>[22]</sup>

## 6.3 Autonomy and Surveillance

Continuous monitoring may create feelings of surveillance, potentially affecting patient trust and independence.<sup>[23]</sup>

## 6.4 Equity and Accessibility

Digital health technologies may widen healthcare disparities if access is limited to affluent populations.<sup>[24]</sup>

## 7. Regulatory Considerations

Digital pill systems are regulated as combination products involving pharmaceuticals and medical devices. Regulatory authorities require:

- Safety evaluation
- Clinical trials
- Data security compliance
- Post-marketing surveillance

Clear regulatory frameworks are essential for ensuring patient safety and public trust.<sup>[25]</sup>

## 8. Future Perspectives

The future of digital pill technology is promising, with ongoing advancements expected to enhance performance and usability.

### Key developments may include

- Artificial intelligence integration
- Predictive analytics
- Miniaturized sensors
- Improved wireless communication
- Expanded clinical applications

Digital pill systems are likely to become an integral part of personalized healthcare and remote patient monitoring.<sup>[26]</sup>

## 9. CONCLUSION

Digital pill systems represent a significant innovation in modern healthcare, providing real-time monitoring of medication adherence and improving patient outcomes. These technologies offer numerous benefits, including enhanced treatment monitoring, improved communication between patients and healthcare providers, and support for personalized medicine.

However, challenges related to cost, privacy, data security, and patient acceptance must be addressed to ensure safe and equitable implementation. Continued research, technological development, and regulatory oversight will be essential for maximizing the potential of digital pill systems in clinical practice.

Digital pill systems have the capacity to transform medication management and healthcare delivery, making them a valuable tool in the future of digital medicine.

**Author Contributions:** All authors contributed significantly to the conception, design, literature review, data interpretation, and preparation of the manuscript. All authors participated in drafting and revising the article critically for important intellectual content and approved the final version of the manuscript for publication.

## ACKNOWLEDGEMENT

The authors express their sincere gratitude to the management and faculty of Laxminarayan Dev College of Pharmacy for providing the necessary facilities, guidance, and support to complete this review work successfully.

## Conflict of Interest

The authors declare that there is no conflict of interest regarding the publication of this manuscript.

## 10. REFERENCES

1. Osterberg L, Blaschke T. Adherence to medication. *N Engl J Med.*, 2005; 353: 487-497.
2. Sabaté E. Adherence to long-term therapies: Evidence for action. World Health Organization, 2003.
3. Farmer KC. Methods for measuring and monitoring medication adherence. *Clin Ther.*, 1999; 21: 1074-1090.
4. Hwang TJ, et al. Digital medicine: A new era of pharmacotherapy. *Clin Pharmacol Ther.*, 2018; 104: 25-27.
5. Kalantar-Zadeh K, et al. A human pilot trial of ingestible electronic capsules. *Nat Electron*, 2018; 1: 79-87.
6. Chai PR, et al. Digital pills to measure opioid ingestion patterns. *J Med Internet Res.*, 2018; 20: e19.
7. Dayer L, et al. Smartphone medication adherence applications. *J Am Pharm Assoc*, 2013; 53: 172-181.
8. Chai PR, et al. Validation of ingestible sensor system. *Telemed e-Health*, 2017; 23: 806-812.
9. Peters-Strickland T, et al. Digital aripiprazole tablet in schizophrenia. *CNS Drugs*, 2018; 32: 1053-1059.
10. Yaghoubian A, et al. Digital adherence monitoring in tuberculosis. *BMJ Open*, 2021; 11: e042348.
11. McGillicuddy JW, et al. Digital medication adherence monitoring in transplant patients. *Transplantation*, 2019; 103: 1134-1141.
12. Vrijens B, et al. A new taxonomy for describing adherence. *Br J Clin Pharmacol*, 2012; 73: 691-705.
13. Steinhubl SR, et al. The emerging field of mobile health. *Sci Transl Med.*, 2015; 7: 283rv3.
14. Brown MT, Bussell JK. Medication adherence. *Mayo Clin Proc*, 2011; 86: 304-314.
15. Kruse CS, et al. Telemedicine use in rural healthcare. *J Med Syst*, 2017; 41: 1-9.
16. Baumgartner T, et al. Digital medicine adherence systems. *NPJ Digit Med.*, 2021; 4: 1-9.
17. Topol EJ. *The patient will see you now*. Basic Books, 2015.

18. IQVIA Institute. Digital health trends report, 2021.
19. Roehrs A, et al. Personal health records review. *J Biomed Inform*, 2017; 70: 103-120.
20. Desai M, et al. Patient acceptability of digital adherence technology. *BMJ Open*, 2020; 10: e036453.
21. Luxton DD. Ethical implications of digital health. Academic Press, 2016.
22. Goodman KW. Ethics of digital health technologies. Cambridge University Press, 2018.
23. Gomez-Temesio V. Ethics of digital pills. *Med Health Care Philos*, 2020; 23: 65-76.
24. World Health Organization. Global digital health strategy, 2020.
25. FDA. Digital health innovation action plan, 2017.
26. Patel MS, et al. Wearable devices for medication monitoring. *J Gen Intern Med.*, 2016; 31: 350-351.
27. Batra S, et al. Smart pill technology overview. *Pharmaceutics*, 2020; 12: 1-10.
28. Shah R, et al. Digital medicine applications. *J Pharm Sci.*, 2021; 110: 123-130.
29. Kumar S, et al. Digital adherence technology review. *Health Technol*, 2022; 12: 345-356.
30. Singh R, et al. Ingestible sensors in healthcare. *Sensors*, 2020; 20: 1-15.
31. Lee J, et al. Remote patient monitoring technologies. *Telemed J E Health*, 2021; 27: 110-118.
32. Chen M, et al. Internet of Medical Things applications. *IEEE Access*, 2020; 8: 1-12.
33. Bhavnani SP, et al. Digital health transformation. *Circulation*, 2019; 139: 1498-1506.
34. Ryu S. Telemedicine history and future. *Healthcare Inform Res.*, 2012; 18: 153-158.
35. Kvedar JC, et al. Connected health technologies. *Health Affairs*, 2014; 33: 194-199.
36. Sharma A, et al. Digital medicine systems review. *Int J Med Inform*, 2021; 149: 104-112.
37. Gupta R, et al. Medication adherence technologies. *J Clin Pharm Ther.*, 2022; 47: 112-120.
38. Mehta N, et al. Smart healthcare monitoring systems. *Biomed Eng.*, 2020; 45: 233-240.
39. Wilson LS, et al. Cost implications of medication nonadherence. *Value Health*, 2014; 17: 144-152.
40. Patel V, et al. Digital health and patient outcomes. *Lancet Digital Health*, 2020; 2: e417-e427.